Posts

Vol.8 No.1 – 2: Folic Acid Conjugated Graphene Oxide Graviola Nanoparticle for Sono-Photodynamic Leukemia Treatment: Up-To-Date Cancer Treatment Modality

By: Mahmoud Matar Mohammad Abu Rakhey1*, Samir Ali Abd El-Kaream2, Daoxin Ma1

1Department of Hematology, Shandong University-Qilu Hospital, China

2Department of Applied Medical Chemistry, Alexandria University-Medical Research Institute, Egypt

Abstract

Background: There is no doubt that one of the largest researcher dilemmas is cancer. Traditional therapeutic options such as chemotherapy, radiation, surgical and combinational treatment are widely accepted to cure or eradicate tumors. Despite chemotherapy being still a very potent weapon for cancer treatment, it is overwhelmingly associated with borders and serious side effects. There is consistently the probability of recurrence and these cancers can evolve resistance to chemotherapy and radiation treatments. Therefore, seeking a new therapeutic option of treatment is necessary to treat tumors accurately and prevent cancer metastasis. Objective: This work was directed at the evaluation of the efficacy of using activated Graviola nano-composite for leukemia targeted therapy. This work was conducted in vitro (two leukemia cell lines), and in vivo (90 leukemia induced mice). Laser and ultrasound were applied as an energy source. Material and methods: In this work, the biological effects of using activated Graviola nano-composite for leukemia targeted therapy were investigated through biophysical, biochemical, and hematological analysis. Results: The results revealed that Graviola nano-composite is a potential promising photo-sono sensitizer for cancer treatment and plays a critical role both in vitro and in vivo for inhibition and induction of cancer cell death. Conclusion: Our results revealed that activated Graviola nano-composite could be applied as a natural nano-sensitizer for sono-photodynamic therapy (SPDT) cancer targeting.

Folic-Acid-Conjugated-Graphene-Oxide-Graviola-Nanoparticle-for-Sono-Photodynamic-Leukemia-Treatment-Up-To-Date-Cancer-Treatment-Modality-1

Download PDF

Vol.6 No.1 – 4: RBC Alloimmunization in Sudanese Multi-transfused Patients

By: Hager Elkobani1, Sahar Elbager1*, Magdi A. Bayoumi2

1Faculty of Medical Laboratory Sciences, University of Medical Sciences and Technology (UMST), Sudan

2Faculty of Medical Laboratory Sciences, Ibn Sina University, Sudan

Abstract

Background: Blood transfusions are a life-saving measure to replace blood lost through severe bleeding or as a life-saving treatment for various hematological conditions. Blood transfusions are high-risk procedures. One of these risks is alloimmunization. Alloimmunization is an immune response to foreign antigens after exposure to genetically different cells or tissues. Alloimmunization is a frequent undesirable outcome of a blood transfusion. In this study, we investigated the frequency of alloimmunization and the factors associated with the development of antibodies in frequently transfused patients. Materials and Methods: A descriptive cross-sectional study carried out in Khartoum, Sudan between November 2017 and March 2018. The study population included 97 multi-transfused patients (Solid tumors, 41; Sickle cell anemia, 31; Leukemia; 25), 52 males and 45 females whose ages ranged between 3-81 years and each subject received a minimum of 2 units of RBCs. The number of blood units transfused varied among patients from 2 to over 20 units depending on the underline disease treatment needs. Antibody screen was performed using four-cell commercially prepared Grifols reagent RBCs and gel impregnated with antihuman globulin. Results: The overall alloimmunization frequency was 22.7%. The alloimmunization frequency in Sickle cell anemia patients was 29.0%, solid tumors patients; 21.9% and 16.0% in leukemic patients. Alloimmunization frequency was independent on a number of units transfused or gender (p value= 0.071, 0.942), respectively. Conclusion: Sudanese multi-transfused patients have higher rates of alloimmunization compared to other countries. It is our recommendation that pretransfusion protocols must include antibody screening. Timely antigen typing of donor’s blood and to transfuse only antigen-negative blood.

RBC Alloimmunization in Sudanese Multi-transfused Patients-converted

Download PDF